Dr. Yang is the Chairman and Co-Founder of Acepodia. Dr. Yang was formerly Executive Vice President at Juno Therapeutics. Prior to Juno, he served as Executive Vice President of Technical Operations at Roche and Genentech, where he was responsible for biopharmaceutical manufacturing, process development, engineering, technical regulatory, quality, procurement, and global supply chain management. Prior to Genentech, he served in various leadership roles in the industry with Merck, General Electric and Life Systems. Dr. Yang earned his B.S. in Engineering from National Chiao Tung University (Taiwan), his M.S. from the University of Cincinnati, and his Ph.D. in Engineering from Ohio State University.

Dr. Hsiao is the Chief Executive Officer, President and Co-Founder of Acepodia. He was awarded Dr. Y-T Lee Prize, which named after Nobel Laureate Dr. Lee, for his research achievement in Chemistry. Dr. Hsiao has extensive research experience in immune cell therapy development, which led to the discovery and invention of Acepodia’s novel cellular immunotherapy development platform, ACC (Antibody-Cell Conjugation) which was from Nobel Prize laureate-Professor Carolyn Bertozzi's pioneering work in the development of biorthogonal chemistry when Dr. Hsiao, Ph.D., worked at her lab. Dr. Hsiao earned his B.S. in Chemistry from National Taiwan University, and his Ph.D. in Chemistry and Molecular Cell Biology from the University of California, Berkeley.

Dr. Lam is a seasoned industrial veteran with extensive leadership experience in biopharmaceutical manufacturing and operations. Prior to join Acepodia, Dr. Lam was CTO and EVP at JW Therapeutics; VP & Head of Biologics Manufacturing at Sanofi; VP of Manufacturing & Technical Operations at Progenitor Cell Therapy; and VP of Manufacturing & Process Development at Shire Regenerative Medicine.

Prior to Shire, Dr. Lam spent 17 years at Genentech/Roche with increasing responsibilities in various functions in South San Francisco and Singapore, including engineering, manufacturing, manufacturing science & technology, and CMO operations. Prior to Genentech, Harry spent 11 years at Pfizer Bioprocess R&D.

Dr. Lam received his B.S. in Chemical Engineering from the University of Birmingham, and his Ph.D. in Chemical Engineering from Rensselaer Polytechnic Institute.

Jennifer has more than 25 years of Quality and CMC experience for CAR-T cell therapy, Antibody therapeutics, and Antibody Drug Conjugates. Jennifer is now the VP of Quality at Acepodia Biotech, Inc., an allogeneic cell therapy company specialized in a patented Antibody Cell Conjugates platform, based in the San Francisco Bay Area and with Operations in Taiwan.

Before joining Acepodia, Jennifer was the Head of Quality at JW Therapeutics in China, working on the development of an autologous CAR-T cell therapy product RelmaCel, which was approved and launched in Sept 2021. Prior to joining JW in 2018, Jennifer worked at Abbvie for 2 years, Genentech for 10 years, and Tanox for 10 years in the US, led a team of scientists/Quality specialists responsible for various CMC and Quality aspects in developing multiple Antibody based therapeutics.

Jennifer earned her B.S. in Chemistry, and M.S. in Chemical Engineering from Tsinghua University in China, and Ph.D. in Chemical Engineering from Texas A&M University in the US.

As a seasoned drug development and regulatory affairs expert with over 25 years in the biopharmaceutical industry, Dr. Mackin has held senior leadership positions in regulatory and manufacturing functions within a number of biopharmaceutical companies and consultant agencies, including Aptuit Consulting. Dr. Mackin received his B.S. in Biology and Microbiology from University of Illinois at Urbana-Champaign, and Ph.D. in Microbiology and Immunology from University of Illinois at Chicago. Dr. Mackin was a post-doctoral fellow at University of Connecticut Health Center. Dr. Mackin also currently serves as President of WMackin & Associates.

Dr. Kurman has spent over forty years in the oncology drug development field. He is a board-certified medical oncologist who practiced community oncology and has participated as an investigator in oncology clinical trials sponsored by the National Cancer Institute. During his career in the pharmaceutical industry, he has held positions of progressive responsibility at Janssen Pharmaceutica, Cytogen Corporation, U.S. Bioscience, and Quintiles’ (now IQVIA) Oncology Therapeutics Division. During his career in the pharmaceutical industry, Dr. Kurman has been involved in the regulatory review or commercial launch of four new oncology products. Dr. Kurman received his B.A., summa cum laude in biology from Syracuse University and his M.D. from Cornell University Medical College. He has held teaching positions at New York University and Stevens Institute and is an entrepreneur-in-residence at the Yale Office of Cooperative Research and a mentor for the Weill Cornell Bioventure eLAB.  

Jessica Lee received her Biotechnology M.S. degree from Northwestern University and M.B.A. degree from China Europe International Business School. Jessica's life science experience spans over 12 years in different roles from researcher, venture capitalist to corporate development. Prior to Acepodia, she held business development positions at CytomX Therapeutics, WuXi Biologics and Eureka Therapeutics where she has successfully either led or facilitated fundraising events and licensing deals with multinational pharmaceutical companies, including Sanofi, Regeneron and Moderna.

Dr. Yang is the Chairman and Co-Founder of Acepodia. Dr. Yang was formerly Executive Vice President at Juno Therapeutics. Prior to Juno, he served as Executive Vice President of Technical Operations at Roche and Genentech, where he was responsible for biopharmaceutical manufacturing, process development, engineering, technical regulatory, quality, procurement, and global supply chain management. Prior to Genentech, he served in various leadership roles in the industry with Merck, General Electric and Life Systems. Dr. Yang earned his B.S. in Engineering from National Chiao Tung University (Taiwan), his M.S. from the University of Cincinnati, and his Ph.D. in Engineering from Ohio State University.

Dr. Hsiao is the Chief Executive Officer, President and Co-Founder of Acepodia. He was awarded Dr. Y-T Lee Prize, which named after Nobel Laureate Dr. Lee, for his research achievement in Chemistry. Dr. Hsiao has extensive research experience in immune cell therapy development, which led to the discovery and invention of Acepodia’s novel cellular immunotherapy development platform, ACC (Antibody-Cell Conjugation) which was from Nobel Prize laureate-Professor Carolyn Bertozzi's pioneering work in the development of biorthogonal chemistry when Dr. Hsiao, Ph.D., worked at her lab. Dr. Hsiao earned his B.S. in Chemistry from National Taiwan University, and his Ph.D. in Chemistry and Molecular Cell Biology from the University of California, Berkeley.

Dr. Yang has many years of experience working in various operations of the global pharmaceutical and biotech industry. She has held management and analytical positions in market analysis at Merck, Genentech and Roche. The most recent position was serving as a VP of business operations for a start-up company. Dr. Yang is an expert in market research, market strategy development, and big data analysis. She received a M.S. from Ohio University and a Ph.D. from Ohio State University.

Dr. Chang is Chairman and CEO of YFY Biotech Management Company and is an adjunct professor at the Institute of Public Health at National Yang-Ming University. Prior to joining YFY Group, Dr. Chang held several key positions in the Taiwanese Ministry of Health and served as President and CEO at the Bureau of National Health Insurance (BNHI) and has extensive experiences in health care and disease control. During Dr. Chang’s tenure at BNHI, he established the Smart Card System for every citizen’s access to health care. Dr. Chang earned his M.D. from National Yang-Ming University and he also received his M.P.H. from National Taiwan University and M.S. in Health Policy and Management from Harvard School of Public Health.

Dr. Yu is Distinguished Chair Professor and Co-Director of the Institute of Stem Cell and Translational Cancer Research at Chang Gung University (Taiwan). She is also the Academician and Visiting Research Fellow of the Genomic Research Center at Academia Sinica (Taiwan), Professor in Pediatrics and Pediatric Hematology and Oncology at the University of California, San Diego. Dr. Yu earned her medical degree from the National Taiwan University, her M.S. from Yale University, and her Ph.D. in Microbiology and Immunology from University of Chicago.

Dr. McCracken has more than 25 years of experience in research, strategic business development and commercial roles in biotechnology and pharmaceutical companies. He was previously vice president and global head of business development and licensing for Roche Pharma, where he was responsible for Roche Pharma’s global in-licensing and out-licensing activities. Prior to joining Roche Pharma, Dr. McCracken held the position of vice president of business development at Genentech for more than nine years, and previously held similar positions at Aventis Pharma and Rhone-Poulenc Rorer. Dr. McCracken holds a B.S. in Microbiology, a M.S. in Pharmacology, and a D.V.M. from Ohio State University. 

Dr. Richard Lopez is Associate Professor of Medicine at Duke University and is also CEO and Founder of PhosphoGam, a biotechnology company developing gamma delta T cell therapies. Dr. Lopez is an experienced medical oncologist specializing in hematology and stem cell therapies.

Dr. Lopez graduated and completed his residency training both in Stanford University School of Medicine.

Dr. Eileen Higham has over 20 years of experience leveraging diverse strategic, scientific, and technical expertise to develop innovative strategies to rapidly deliver novel cell-, viral-, and protein-based therapies to improve human health.

Dr. Higham is currently Senior Vice President, Head of Technical Operations at Intergalactic Therapeutics, a stealth non-viral gene therapy company. Prior to Intergalactic, Dr. Higham was Vice President, Head of Analytical & Process Development at Sana Biotechnology, where she led a team developing best-in-class manufacturing processes and analytical packages for production of next generation cell and gene therapies. Prior to Sana, Dr. Higham was Senior Director, Head of Analytical & Process Development at Juno Therapeutics (Celgene/Bristol Myers Squibb), where she provided strategic, scientific, and technical leadership for development of best-in-class manufacturing processes and analytical packages for production of autologous T cell therapies. In this role, she led an organization of 100+ scientists and engineers developing strategies to enable robust, well-controlled, and well-characterized Drug Product process design and associated analytical packages to support Phase 0 through commercialization.  Prior to Juno, Dr. Higham served as Associate Director/Product Development Team Leader - Adoptive Cellular Therapy at MedImmune/AstraZeneca, with joint appointments in Biopharmaceutical Development (BPD) and the Oncology Innovative Medicines Unit (iMED). Dr Higham started her career in industry at Merck as a Biochemical Engineer developing in-house, serum-free cell culture media for use in the efficient-large scale production of viral products.

Dr. Higham received a Bachelor of Science in Engineering in Chemical Engineering from Princeton University and a Doctorate in Biological Engineering from the Massachusetts Institute of Technology.